Alterations in the mechanical properties of erythrocytes occurring in inflammatory and haematological disorders such as sicklecell disease (SCD) and malaria often lead to increased endothelial permeability, haemolysis and microvascular obstruction. However, the associations among these pathological phenomena remain unknown. Here, we show that a perfusable, endothelialized microvasculature-on-a-chip featuring an interpenetrating-polymer-network hydrogel that recapitulates the stiffness of blood vessel intima, basement membrane self-deposition and self-healing endothelial barrier function for longer than one month enables the real-time visualization, with high spatiotemporal resolution, of microvascular obstruction and endothelial permeability under physiological flow conditions. We found that extracellular haem-a haemolytic by-product-induces delayed yet reversible endothelial permeability in a dose-dependent manner, and demonstrate that endothelial interactions with SCD or malaria-infected erythrocytes cause reversible microchannel occlusion and increased in situ endothelial permeability. The microvasculature-on-a-chip enables mechanistic insight into the endothelial barrier dysfunction associated with SCD, malaria and other inflammatory and haematological diseases.
T he vascular endothelium defines the interface between blood and tissue, forming a semi-permeable barrier that controls the exchange of nutrients and soluble factors 1, 2 . In numerous haematological and inflammatory diseases, such as sickle-cell disease (SCD) and malaria, endothelial barrier dysfunction is associated with the pathophysiological hallmarks of these disorders; specifically, the polymerization of sickle haemoglobin in red blood cells (RBCs) in SCD and in RBC infection with Plasmodium parasites in malaria, leading to microvascular obstruction and haemolysis [3] [4] [5] [6] . Although animal models have vastly improved the understanding of these diseases, the underlying mechanisms of endothelial barrier dysfunction in SCD and malaria remain unknown, owing to the complex interplay of in vivo factors that are difficult to manipulate and the different pathological phenotypes between animals and humans [7] [8] [9] [10] [11] . Therefore, complementary in vitro microvascular systems that feature human endothelial cells are needed to provide a reductionist, quantitative insight into endothelial barrier dysfunction in SCD, malaria and other haematological disorders.
Although perfusable microvascular networks can be engineered in solid polymeric materials, these possess moduli ranging from 50 kPa to several MPa [12] [13] [14] , which is much higher than the stiffness of tissues surrounding blood vessels, and can lead to endothelial dysfunction and compromise the engineered endothelial barrier function 15, 16 . In contrast, hydrogel materials can be fine-tuned to a more physiologically relevant stiffness (approximately hundreds of Pa to 50 kPa) and have thus been widely used for engineering microvascular networks. Hydrogel-based perfusable microvascular networks can be engineered by bottom-up approaches via vasculogenesis and angiogenesis [17] [18] [19] [20] , which is valuable for studies such as cancer metastasis and angiogenesis. However, these microvascular networks exhibit instability in vascular size, length and geometry, which results in uncontrollable flow patterns. Although top-down approaches can fabricate hydrogel microchannels with precise size and geometry and enable well-defined and controlled flow patterns [21] [22] [23] [24] [25] [26] [27] [28] , most of these approaches involve fabricated microchannels with a size that is not smaller than 50 μ m. Although some groups have engineered in vitro microvasculature models down to 20 μ m, they are only limited to straight channels 29 . No top-down approach has been reported for the engineering of vasculature networks with branches at the microvasculature size scale (< 30 μ m), which is more suitable for the investigation of endothelial barrier function in haematological disorders of the microcirculation, such as SCD and malaria. Moreover, no published reports to date have described in vitro microvasculature models that maintain appropriate physiological barrier function long-term (weeks to months) to investigate not only endothelial dysfunction, but also the restoration of barrier integrity after an acute complication or insult is removed.
Microvasculature-on-a-chip for the long-term study of endothelial barrier dysfunction and microvascular obstruction in disease
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To this end, we employed an agarose-gelatin interpenetratingpolymer-network (IPN) hydrogel to develop an endothelialized microvascular-sized fluidic system using a top-down approach. Specifically, this hydrogel-based IPN microfluidic device mimics the in vivo diameter of post-capillary venules and the corresponding wall shear stress, as well as the stiffness of the blood vessel intima, which collectively enables the cultured endothelial monolayer to appropriately assemble a laminin-rich and collagen IV-rich basement membrane and maintain barrier function for over one month under continuous laminar flow conditions. Using this microvasculature-on-a-chip system, we elucidated how inflammatory mediators, haemolytic by-products and pathologically altered RBCs that lead to microchannel obstruction in haematological diseases spatiotemporally alter barrier function and affect the subsequent recovery of barrier function. This hydrogel-based endothelial-network system demonstrates significant promise for investigating how molecular and cellular interactions directly mediate microvascular endothelial barrier dysfunction in a wide spectrum of other diseases.
Results
Engineering a hydrogel-based microvasculature-on-a-chip using an IPN with physiologically relevant stiffness. To fabricate perfusable microvascular-sized channels that allow for the study of microvessel occlusion, we applied conventional microfluidic techniques to an agarose-gelatin IPN (Fig. 1a) . A silicon master mould of branching microchannels was fabricated via standard photolithography; the smallest channels were 20 µ m in width and height to approximate the post-capillary venule size 14 (Fig. 1b) . High-fidelity transfer of the patterned microvasculature network from the master mould to an IPN hydrogel was achieved by casting the agarose-gelatin solution in the mould at 65 °C and removing the solidified IPN hydrogel from the mould at 4 °C. This enabled the high-throughput production of multiple identical hydrogel-based microdevices from a single master mould. To ensure constant microchannel perfusion and prevent stiff inlet tubing from damaging the IPN hydrogel, a silanized polydimethylsiloxane (PDMS) adaptor layer was glued to the hydrogel channel layer via a gelatin layer. The bottom hydrogel layer (~200 µ m thick) was then covalently attached to a silanized glass cover slide ( Fig. 1c ) to allow for high-resolution videomicroscopy. To prevent microchannel collapse resulting from a housing or clamping system 27, 30 , we covalently bonded each layer together via gelatin using carbodiimide crosslinker chemistry ( Fig. 1d) 31 . The stiffness of the tissues surrounding healthy arteries was reported to be ~35 kPa 15, 16, 32 and the stiffness of the softest tissues in the body was found to be ~1 kPa 33 . We therefore deduced that the tissues surrounding microvasculature have a stiffness between 1 and 35 kPa, and fine-tuned the Young's modulus (E) of the IPN (Fig. 1e ) to ~20 kPa using 1% (w/v) agarose and 1% (w/v) gelatin. After endothelial cell seeding, the microdevice was immersed in culture medium ( Fig. 1f ), allowing fluid to freely diffuse across the IPN hydrogel layers. The endothelial cells reached confluence one to two days post-seeding and spanned the threedimensional inner surface of the microchannels under laminar flow conditions ( Fig. 1g ). Due to the microvascular size scale of our microchannels, in which the size of the endothelial cells approximated that of the microchannels, the presence of endothelial cells cultured in the channels led to a 'rounding out' of the luminal space ( Supplementary Fig. 1 ). To recapitulate the flow in 20-μ m-diameter post-capillary venules 34, 35 , the average flow velocity in the smallest channels was set to ~2.8 mm s -1 (Fig. 1h) , which corresponded to a wall shear stress of ~8.8 dynes cm -2 (computational fluidic dynamic modelling in Supplementary Fig. 2 ). Under these continuous, constant flow conditions, endothelial cells aligned with the direction of flow in the microchannels ( Supplementary Fig. 3 ). The versatility of the system was evidenced by our ability to culture endothelial cells obtained from different vascular beds: human umbilical vein endothelial cells (HUVECs), human dermal microvascular endothelial cells (HDMVECs) and human lung microvascular endothelial cells (HLMVECs).
Permeability of the microvasculature-on-a-chip recapitulates the endothelial barrier function of the microcirculation over long (>1 month) timescales.
All tested endothelial cell types maintained a functional, semi-permeable barrier in our hydrogel microchannels one month post-seeding under continuous laminar flow conditions, without lumen collapse. The cultured endothelium in our engineered IPN microvasculature appropriately assembled its own basement membrane, depositing a continuous sheet of both laminin and collagen IV ( Fig. 2a,b and Supplementary Figs. 4 and 5). Moreover, the physiological conditions of our system enabled the endothelial cells to continuously and dynamically remodel their basement membrane, which occurred in vivo, as evidenced by the endothelial expression of matrix metalloproteinase-2-a collagen IV-cleaving enzyme ( Supplementary Fig. 6 ). In contrast, endothelial cells cultured in PDMS-based microfluidic devices, which were significantly stiffer, did not assemble a basement membrane ( Supplementary Fig. 7 ). Importantly, the engineered microvasculature from all three endothelial cell types expressed continuous vascular endothelial cadherin under physiological laminar flow, indicating the physiological formation of adherens junctions, and thus establishing endothelial barrier integrity 36 (Fig. 2b , Supplementary Video 1 and Supplementary Figs. 4 and 5). When perfused with Alexa Fluor 594-tagged bovine serum albumin (BSA-AF594), control acellular microdevices showed significant leakage within 3 min of perfusion ( Fig. 2f ), while endothelialized microdevices maintained barrier integrity throughout the 15-20 min measurement period ( Fig. 2c-e ). To further characterize this aspect of our system, the apparent permeability coefficient (P a ) of BSA-AF594 was quantified by measuring the fluorescence intensity in the smallest channels over 15 min of perfusion ( Supplementary Fig. 8 and Supplementary Videos 2 and 3). We found that our engineered microvasculatures with HUVECs, HDMVECs and HLMVECs all exhibited a permeability of ~4 × 10 -7 cm s -1 (~40 times lower than acellular microdevices), similar to mammalian venules ((1.5 ± 0.5) × 10 -7 cm s -1 ) in vivo 12, 37 and lower than most previously reported in vitro model values 12, 27, 30 (Fig. 2g ,h). The apparent permeability of the engineered microvasculature was confirmed by perfusion of an alternative molecular tracer, fluorescein isothiocyanate-conjugated 70 kDa dextran ( Supplementary Fig. 9 ). The permeability of the engineered microvasculature was significantly increased when agarose-gelatin IPNs of higher stiffnesses (~50 kPa) were used. In contrast, endothelial cell culture in the softest devices (~5 kPa) was not feasible, probably due to the weaker mechanical stability compared with the stiffer devices, which could not sustain the wall shear stress and intravascular pressure within the microchannels ( Supplementary  Fig. 10 ). These data suggest a critical role of substrate stiffness in regulating the endothelial barrier function, consistent with previous reports 15, 16 . Furthermore, unlike other currently existing systems, our engineered microvasculature maintained stable barrier function one month post-seeding ( Fig. 2h ). Taken together, these data indicate that by mimicking key biological and biophysical features of the in vivo microvasculature, our hydrogel-based microdevices enable long-term preservation of endothelial barrier function in vitro. This system then allows pathologically altered RBCs-with or without associated inflammatory mediators-to be perfused into the engineered microvasculature under physiological flow conditions, and the spatiotemporal effects on barrier function to be quantitatively assessed via perfusion of a fluorescent molecular tracer ( Supplementary Fig. 11 ).
Engineered microvasculature responds in a physiological manner to barrier-disrupting inflammatory mediators and shows
NATure BiomeDiCAl eNgiNeeriNg self-healing of the endothelial barrier integrity. Since elevated levels of the inflammatory cytokine tumour necrosis factor-α (TNF-α ) in both SCD and severe malaria contribute to endothelial barrier dysfunction 38, 39 , we sought to investigate how TNF-α affects permeability in our engineered microvasculatures. Overnight exposure to 10 ng ml -1 TNF-α ( Fig. 3a) induced HUVEC permeability throughout the microvasculature and resulted in a ~20-fold increase in permeability ( Fig. 3b ,c). Consistent with previous findings 40, 41 , TNF-αstimulated endothelium shows upregulation of multiple adhesion molecules, including E-selectin, vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) ( Fig. 3d ), but not P-selectin ( Supplementary Fig. 12 ). The long-term culture under physiological flow conditions allowed by our system revealed that the barrier function of engineered microvasculature 
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gradually 'self-healed' after the removal of TNF-α : the permeability reduced to ~2.9 × 10 -6 cm s -1 2 days post-exposure and ~1.0 × 10 -6 cm s -1 4 days post-exposure. Our system thus responds to cytokine stimuli in a physiologically relevant manner, and reveals the endothelium's ability to self-heal barrier function 42 .
To further characterize our engineered microvasculature, we assessed how free haem-a haemolytic by-product-directly affects endothelial permeability ( Fig. 3e ). Studies by our group and others suggest that the high levels of extracellular haem released into the circulation upon RBC destruction in both SCD and malaria cause endothelial barrier dysfunction [43] [44] [45] . However, because the effects of extracellular haem in vivo are confounded by factors such as increased concentrations of cytokines and/or the presence of activated cells (monocytes, lymphocytes, platelets and so on), the effect of free haem itself on the endothelial barrier is unclear 38 . Using the reductionist approach our system enables, we found that the 1 h perfusion of haemin at SCD-relevant concentrations of 5-10 µ M 43-45 increased HUVEC permeability. Interestingly, permeability peaked at one day post-haemin exposure. Importantly, we found that the haemin-induced endothelial permeability occurred in a dose-dependent manner ( Fig. 3f-h ). Exposure to 5 µ M free haemin for 1 h resulted in around an eightfold increase in permeability, with a return to baseline permeability 4 days post-exposure. In contrast, exposure to 10 µ M free haemin resulted in around a 30-fold increase in permeability, and it did not return to baseline within 4 days. This dosedependent, delayed permeability effect by free haemin was further confirmed in the engineered microvasculature using HDMVECs ( Supplementary Fig. 13 ). Collectively, these experiments establish that the engineered microvasculature responds physiologically to inflammatory mediators and haemolysis by-products. In addition, our data not only answer a current question in SCD by confirming d, Fluorescence intensity of BSA-AF594 along the linescan across the engineered microvasculature in c. e, Higher-magnification view of the engineered endothelialized microvasculature after 15 min perfusion of BSA-AF594, demonstrating that the system is impermeable to BSA-AF594 under physiological flow conditions. f, In acellular (non-endothelialized) microsystems, significant diffusion of BSA-AF594 occurred after just 5 min perfusion (dashed lines define the microchannel borders). g, Representative plots of BSA-AF594 fluorescence intensity over time in permeability assays for both acellular and endothelialized microdevices. h, Quantified P a values of the engineered microvasculatures in response to BSA-AF594 remained similar across different endothelial cell types and were approximately 40 times less than in acellular microchannels. Data are plotted as means ± s.d. (n = 4 independent biological replicates, expect for HLMVECs (n = 3)). P values were calculated using one-way ANOVA with Bonferroni's post-hoc test (***P < 0.001; NS, not significant). The permeability of the engineered microvasculatures was stably maintained for over 4 weeks (measured at multiple sequential time points).
that haem directly causes a loss of endothelial barrier function, but also provide insight into the temporal pattern of this effect and its resolution over time.
Sickle erythrocyte-endothelial cell interactions induce microchannel occlusion and a loss of endothelial barrier function.
Chronic vasculopathy and vaso-occlusion crises are associated with SCD 5, 6, 8, 9 ; however, the lack of mechanistic understanding of how these pathologies are linked prevents the development of effective therapeutics. While it is well-established that the endothelium interacts with sickle RBCs, including the irreversibly sickled RBC (ISC) subpopulation 9 , it remains unclear whether sickle RBC-endothelium interactions are sufficient to increase vessel permeability and cause vaso-occlusion. Our system allows for the effective decoupling of the effects of RBCs from other cofounding in vivo factors-other cell populations, cytokines and coagulation proteins. Initial experiments revealed that the 4 h perfusion of RBCs isolated from a population of SCD patients induced microchannel occlusion and led to increased HUVEC permeability at the exact site of the obstruction (Fig. 4a ). To further investigate how sickle RBCs induce 
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in vitro microvascular occlusion and endothelial permeability, we correlated the phenomenon with the morphology of sickle RBCs, and discerned two experimental scenarios (Fig. 4b ).
All SCD patients have a percentage of ISCs 46 that maintain pathologically increased stiffness and sickled shape even under normoxic conditions and are known to be involved in the pathophysiology of 
Fig. 4 | interactions between sickle RBCs and endothelial cells induce microchannel occlusion and loss of endothelial barrier function in the engineered
microvasculature. a, Representative 3D confocal microscope images of endothelialized microchannels occluded by sickle RBCs (pre-stained with R18; indicated by arrows), and the resultant, co-localized increased endothelial permeability and leakage of BSA-AF488 in situ. b, Representative brightfield images of blood smears reveal two experimental scenarios involving our SCD patients' blood samples. c, Experimental timeline and design. d, Representative stitched-composite-of-epifluorescence images indicate that perfusion of low percentages of ISCs for 4 h caused no change in permeability in the engineered microvasculature. e, Representative stitched-composite-of-epifluorescence and brightfield microscopy images of the boxed regions indicate that perfusion of high percentages of ISCs for 4 h caused temporary microchannel occlusion and was sufficient (in the absence of other blood cell populations or exogenous inflammatory mediators) to induce loss of endothelial barrier function and increased permeability in the engineered microvasculatures. Within 1 day of continued culture and perfusion, the ISC microchannel occlusion cleared and the engineered microvasculature 'selfhealed', gradually recovering its barrier function (black arrow, adherent sickle RBCs; white arrow, RBC aggregate occluding the microchannel). f, Quantitative apparent permeability measurements of the BSA-AF594 tracer at different time points both pre-and post-perfusion of ISCs from SCD patients. Data are plotted as means ± s.d. (n = 3 independent replicates; in each condition, blood samples were collected from three different patients and perfused into three different devices). P values were calculated using two-way ANOVA with Bonferroni's post-hoc test (*P < 0.001).
NATure BiomeDiCAl eNgiNeeriNg
the disease (Fig. 4b) . When the blood from SCD patients had a low percentage of ISCs (~2.5%) (morphological analysis using ImageJ (https://imagej.nih.gov/ij/download.html) as described in the Supplementary Information), 4 h perfusion of RBCs did not affect endothelial permeability (Fig. 4c-f and Supplementary Video 4) , as was the case for perfusion of RBCs from healthy individuals ( Supplementary Fig. 14) . In contrast, when SCD patients had a significantly higher percentage of ISCs (~14.4%; Fig. 4b ), RBCs adhered to the engineered microvasculature and in vitro vaso-occlusion occurred in some microchannels after 4 h of perfusion, which obstructed the entire microchannel and completely ceased the flow of RBCs through those microchannels ( Fig. 4e and Supplementary Video 5). Furthermore, the permeability increased around twofold at the exact sites of sickle RBC adhesion (Fig. 4f ). However, these interactions did not lead to stable sickle RBC adhesion or sustained in vitro vaso-occlusion under flow conditions, as both were eliminated one day after RBC perfusion (Fig. 4e) . Importantly, endothelial permeability returned to baseline pre-perfusion levels (Fig. 4f ). Since ISCs are stiffer than normal RBCs, we investigated whether the increased stiffness of RBCs alone can induce endothelial permeability. Accordingly, normal, healthy RBCs were exposed to 0.065% glutaraldehyde, which leads to RBC stiffnesses similar to those of ISCs 47, 48 . RBC suspensions containing 15% of these stiffened RBCs were perfused through the endothelialized channels. Interestingly, four-hour perfusion increased the permeability of the engineered endothelium, and complete in vitro occlusion and the cessation of the flow of RBCs were also observed in some microchannels ( Supplementary Fig. 15 ), suggesting that the elevated stiffness of ISCs contributes to the increased permeability of engineered endothelium. As ISCs are both stiffer than normal, healthy RBCs and harbour pathological adhesive properties that may induce downstream endothelial pro-inflammatory signalling, this experiment demonstrates that increased RBC stiffness alone may disrupt endothelial barrier function without the need for ligand-receptor adhesion, and highlights our system's capability to decouple biophysical from biological phenomena. Our data show that the interaction of a high ratio of artificially stiffened RBCs or ISCs with the endothelium is sufficient to cause microvascular permeability and occlusion at RBC adhesion sites. Moreover, we demonstrate the capability of our engineered microvasculature to assess pathological blood cell-endothelial interactions over longer timescales than existing in vitro systems, thereby enabling investigation of the resolution of cellular interactions in haematological diseases and fulfilling an unmet clinical and scientific need.
Plasmodium falciparum-infected RBCs (iRBCs) act alone and in concert with TNF-α to disrupt endothelial barrier function.
Cerebral malaria is a life-threatening complication of malaria characterized by the loss of endothelial barrier function 10, 49, 50 , the underlying mechanism of which has long been debated 7, 10 . It is currently unknown which combination of factors-cytoadhesion of iRBCs, inflammatory cytokines, haemolysis and/or direct interactions with immune cells-are required to induce loss of endothelial barrier function in cerebral malaria. Our engineered microvasculature can decouple the complex factors implicated in the pathogenesis of cerebral malaria to address this question (Fig. 5a ). We found that perfusion of iRBCs alone resulted in around a twofold increase in HUVEC permeability ( Fig. 5b-d) at the locations of iRBC cytoadhesion (Fig. 5b,c and Supplementary Video 6), whereas the occlusion was barely observed in the microchannels. Post-iRBC perfusion, the permeability recovered to baseline levels in two days (Fig. 5d ). During healing of endothelial barrier integrity, the endothelium engulfed the malarial pigment hemozoin (a by-product), indicating that it is not associated with increased endothelial permeability ( Fig. 5b-d) .
To study how humoural and cellular interactions synergistically affect endothelial barrier function in cerebral malaria, we stimulated the engineered microvasculature with 10 ng ml -1 TNF-α overnight, followed by 4 h perfusion of iRBCs ( Fig. 5e,f) . TNF-α stimulation resulted in enhanced microchannel occlusion and near-complete obstruction of the microvasculature system by perfused iRBCs. Two days post-iRBC perfusion, microchannels remained completely occluded by the initial adherent iRBC aggregates and a growing hemozoin aggregate was present (Fig. 5g,h) . It is likely that this in vitro occlusion was sustained by the reduction of media flow due to the presence of large aggregates, which thereby allowed ongoing interactions between iRBCs and endothelial cells. Taken together, our data suggest that iRBC presence alone has the capacity to induce endothelial barrier dysfunction. Stimulation by inflammatory cytokines such as TNF-α further exacerbates microvascular occlusion, leading to severe cerebral malaria. Thus, our findings support the critical role played by iRBCs and inflammatory cytokines in vascular dysfunction and leakage, features commonly observed in cerebral malaria 7, 10 .
discussion
We took a top-down approach and leveraged IPNs to develop a microvasculature-on-a-chip endowed with the following features that have not been reported by existing in vitro models (Supplementary Table 1 ): (1) it features a three-dimensional (3D) endothelial network at the microvascular size scale (20 μ m) with well-controlled flow patterns;
(2) it allows for long-term culture of endothelium under well-controlled flow conditions that mimic microvascular shear stress; (3) the engineered endothelium self-deposits appropriate basement membrane proteins and displays physiological endothelial barrier function for several weeks; (4) it enables quantitative assessment of endothelial permeability and real-time observation of in vitro vasoocclusion with high spatial resolution; and (5) it recapitulates in vivo recovery of endothelial barrier function, thereby enabling the study of this process in vitro. These features enable a more physiological microvascular environment in our device compared with other in vitro models, which is crucial for studying the endothelial barrier dysfunction in SCD and malaria. For example, vaso-occlusion in SCD and microvascular obstruction in malaria more readily occur in blood vessels of the microcirculation size scale (< 30 μ m) due largely to the restricted lumen spaces. Our model mimics the lumen diameter of post-capillary venules and the corresponding wall shear stress, thus enabling study of the vaso-occlusion that occurs in vivo. Moreover, the endothelial barrier dysfunction and integrity restoration in inflammatory diseases is a chronic process. While existing in vitro systems are primarily conducive to studying acute events (for example, sickle-cell vaso-occlusion, microvascular occlusion with malaria and thrombosis), our system enables longterm studies and culture, and is therefore conducive for studying the recovery of acute events that obviously occur in vivo. This cannot be accomplished with existing in vitro technologies. Furthermore, we can also study how repeated insults affect endothelial function over time to determine how chronic endothelial dysfunction develops, which is the hallmark of many inflammatory and vascular diseases, such as heart disease and sickle-cell vasculopathy.
These attributes of the system properties are due to the integrated hydrogel material, the fabrication process and optimized culture conditions. Since extracellular matrix stiffness regulates endothelial cell proliferation 51 and vascular endothelial growth factor signalling 52 , and increased matrix stiffness is associated with endothelial barrier dysfunction in diseases such as atherosclerosis 15, 16 , creating a system with appropriate stiffness can augment the physiological relevance of the engineered microvasculature and facilitate physiological endothelial barrier function 15 . The agarose-gelatin IPN hydrogel allows us to tune the stiffness to approximate that of the blood vessel intima-a feat not achievable by the solid polymeric materials used in existing vasculature models. Unlike synthetic hydrogels, agarose hydrogels minimally swell or shrink 53 , thus allowing high-fidelity
NATure BiomeDiCAl eNgiNeeriNg transfer of network patterns during 'top-down' fabrication. In addition, gelatin molecules in the IPN system not only provide adhesive domains for initial cell adhesion, spreading and migration, but also function as bonding molecules to allow assembly of the multiple layers via carbodiimide crosslinker chemistry. This assembly scheme is paramount to the system as it ensures physiological laminar flow for the entirety of the cell culture time period, thereby facilitating establishment and maintenance of physiological barrier function.
Previous studies suggest that the pathology of SCD and malaria is closely associated with endothelial barrier dysfunction. However, the processes by which this endothelial barrier dysfunction initiates and progresses in the contexts of these diseases are largely unknown. Our model enables the decoupling of complex factors in the pathological progression of endothelial dysfunction and vasculopathy to determine the effect of pathological molecular and cellular interactions on endothelial barrier function in these diseases, which is unachievable using animal models and current in vitro systems. Our data indicate that the haemolytical by-product haemin, irreversibly sickled RBCs and malaria-infected RBCs are all independent contributors to endothelial barrier dysfunction. Indeed, our system reveals the endothelium's previously uncharacterized, unique dose-dependent and temporal response to the haemolytical by-product haemin [43] [44] [45] , and demonstrates that interactions between the endothelium and pathological RBCs-specifically sickle RBCs 
NATure BiomeDiCAl eNgiNeeriNg
and malaria-infected RBCs-under physiological flow conditions directly lead to increased endothelial permeability at the site of interaction. By demonstrating that interactions between the endothelium and iRBCs are sufficient to induce endothelial barrier dysfunction in malaria and do not require recruitment of other cells, such as lymphocytes, our studies provide insight into a longstanding debate within the field 7 . If unresolved, these chronic interactions between pathological RBCs and haemolysis with the endothelium may lead to chronic endothelial barrier dysfunction and vasculopathy in patients with SCD and malaria, further bolstering the clinical relevance of our studies. Future work involving longer perfusion times that lead to more significant endothelial barrier dysfunction in our model, as well as longer experiments (> 2 months), may provide further insights into chronic SCD vasculopathy over time, which no in vitro system is currently capable of. Furthermore, the long-term nature of the experiments enabled by our system allows for assessing the biological events that occur during resolution of acute complications such as sickle-cell vaso-occlusion or malarial microvascular obstruction-a capability that has not been reported in other in vitro systems. Our studies also suggest that our device could be used as a system to further study how molecular and cellular interactions directly affect the underlying pro-inflammatory signalling pathways of endothelial barrier dysfunction in these diseases, and to screen for drugs and therapeutic strategies in preventing endothelial barrier dysfunction.
In summary, we have engineered endothelialized, IPN hydrogelbased microvascular-on-a-chip systems that recapitulate the size scale, flow conditions and physiology of the microcirculation for a variety of different endothelial cell subtypes and exhibit appropriate barrier function that can be monitored with high spatiotemporal resolution and over long time scales. Using the engineered microvasculature, we have provided insight into the direct effects of the hallmark pathological molecular and cellular interactions in SCD and malaria on endothelial barrier function. This endothelial-permeability system can be readily applied to the study of microvascular endothelial barrier function in other relevant diseases, and holds promise as a research-enabling and drug-discovery system.
Methods
Fabrication of IPN hydrogel-based microdevices. The silicon wafer master mould was fabricated using standard photolithography, in which the geometric pattern of the smallest channels was designed as 20 µ m in width and height. 1% (w/v) agarose (Sigma-Aldrich) and 1% (w/v) gelatin from porcine skin (Sigma-Aldrich) were dissolved in MES (Sigma-Aldrich) buffer (pH 5.3) by heating. The solution was then poured onto the master mould and solidified at 4 °C. The solidified agarose-gelatin IPN gel was peeled off the master mould so that the geometric pattern was transferred to the IPN hydrogel. The PDMS adaptor layer was silanized with trimethoxypropylsilane (Sigma-Aldrich) 54 , then exposed to 0.05% glutaraldehyde aqueous solution for 30 min. After rinsing with deionized water, 8% (w/v) gelatin solution was added to the silanized PDMS surface to form a thin layer. Once the gelatin solution solidified, the agarose-gelatin channel layer was placed onto the gelatin layer with the channel side facing up. Two holes were then punched through the IPN channel, gelatin glue and PDMS adaptor layers as an inlet and outlet, respectively. To fabricate the bottom hydrogel layer, the cover slide was silanized and treated with glutaraldehyde using the same protocol used for the PDMS adaptor layer. Agarose and gelatin solution was then added onto the treated cover slide to form a thin layer (~200 μ m) of IPN hydrogel at 4 °C. The hydrogel channel layer was then placed onto the bottom layer with the channel side facing the bottom hydrogel layer. Finally, the assembled device was immersed in EDC-NHS (Sigma-Aldrich) MES solution at 4 °C for overnight. The cross-linked and covalently bound devices were then washed with 1× phosphate buffered saline (PBS) 6 times and kept in 1× PBS before seeding with endothelial cells.
Elastic modulus measurement using atomic force microscopy nanoindentation.
The Young's modulus of cross-linked gelatin-agarose gels was measured using an MFP-3D atomic force microscope (Asylum Research). Measurements were collected in contact mode using a silicon nitride probe with Cr/Au reflex coating and a 0.09 N m -1 nominal spring constant (BL-TR800PB; Asylum Research). Exact spring constants were determined on glass using force curves and a thermal spectrum calibration via the MFP-3D software. Force curves were collected in a 20 × 20 array with a trigger point of 0.3 V and analysed with the MFP-3D analysis tools using the Hertz model (Poisson ratio = 0.5) with cone as the tip geometry. Three force maps were collected in separate areas on each sample and averaged for the sample value. Three samples were measured per condition with sample values averaged for the condition value. Condition error represents the s.d. between sample averages.
Engineering microvasculature-on-a-chip using IPN hydrogel-based microdevices. HUVECs (passages 3-6; Lonza) and HLMVECs (passages 3-6; Lonza) were maintained in EGM and EGM-2-MV medium, respectively. HDMVECs (passages 3-6; Thermo Fisher Scientific) were maintained in HDMVEC culture medium (Thermo Fisher Scientific). Before endothelial cell seeding, microdevices were immersed in the cell culture medium for overnight. To endothelialize the microdevices, the endothelial cells were detached from the culture flask and resuspended in the culture medium containing 8% dextran (MW 70,000; Sigma-Aldrich) at a concentration of ~5 × 10 6 cells ml -1 . The cell suspension was then injected into the microchannels. After the endothelial cells attached and spread in the microchannels, the microdevices were connected to a syringe (Becton Dickinson) full of cell culture medium using #30 thin wall PTFE tubing (Cole-Parmer), which was driven by a pump (Harvard Apparatus), and cultured under an appropriate constant laminar flow. To immunostain vascular endothelial cadherin, collagen IV and laminin, the endothelial cells were first fixed with 4% paraformaldehyde and permeabilized with 0.05% Triton X. The fixed engineered microvasculature was then blocked by perfusion of 1% BSA solution, followed by perfusion of the primary antibody: mouse anti-human vascular endothelial cadherin (F-8) (1:10; Santa Cruz Biotechnology), mouse anti-human collagen IV (1:100; Abcam) or rabbit anti-human laminin (1:100; Abcam). After it was washed with 1% BSA, the fixed microvasculature was perfused with secondary antibodygoat anti-mouse Alexa Fluor 488 (1:100; Invitrogen) or goat anti-rabbit Alexa Fluor 647 (1:100; Invitrogen) with Hoescht 33342 (1:1000; Sigma-Aldrich). After perfusion with 1× PBS, the stained microvasculature was imaged using confocal microscopy (Zeiss LSM 700).
Computational fluid dynamics modelling in the microchannels. Based on cross-sectional confocal images of our engineered endothelium, the corners of the microchannels were correspondingly rounded using a curvature with the radius of 10 μ m using SolidWorks (https://www.solidworks.com/). The computational fluid dynamics modelling was performed using COMSOL software (https://www. comsol.com/). As the outlet was exposed to the atmosphere, the outlet boundary condition was set as a pressure outlet at 1 atm. The fluid viscosity was set as 7.8 × 10 -4 Pa· s-the reported viscosity of cell culture medium 55 . We also considered the channels as impermeable to fluid in the computational model, as the flux of fluid across the membrane was negligible compared with the volume of fluid perfused through the channel 55 .
Quantitative assessment of endothelial permeability. The permeability assay was carried out, and the P a of BSA-AF594 or BSA-AF488 (Invitrogen) of the engineered microvasculature was quantitatively analysed using an equation adapted from a previously published protocol (equation (1)) [56] [57] [58] . To ensure the concentration used in the permeability assay was suitable for the equation, a calibration was carried out using PDMS-based microfluidic devices containing a same geometric pattern as IPN hydrogel-based microdevices. The employed concentration of the BSA tracer (50 μ g ml -1 ) was determined within the concentration range (0-100 μ g ml -1 ), in which fluorescence intensity of the BSA tracer had a linear relationship with the BSA concentration ( Supplementary Fig. 16 ). During the permeability assay, the cell culture medium containing 50 µ g ml -1 BSA-AF593 (Invitrogen) was perfused into the engineered microvasculature or acellular microdevices for 15-20 min. The imaging field was set to include all four smallest channels ( Supplementary  Fig. 8 ), and the epifluorescence images were taken every 30 s during a period of 15-20 min. To quantitatively analyse the apparent permeability of the engineered microvasculature, a window 120 µ m wide and 160 µ m long was drawn across the microchannel, and the fluorescence intensity within this preset window was measured using ImageJ and plotted against time ( Fig. 1l, Supplementary Fig. 8 and Supplementary Videos 2 and 3 ). The P a of BSA-AF594 of the engineered microvasculature was then calculated according to equation (1). where P a is the apparent permeability coefficient, I 0 is the initial intensity, I 2 is the intensity at t 2 , I 1 is the intensity at t 1 and a is the width of the channel.
Investigation of the responses of engineered microvasculature to the barrier-disrupting inflammatory mediators TNF-α and free haemin. To ensure the engineered microvasculature exhibited an appropriate endothelial barrier function, the permeability assay was carried out before TNF-α stimulation. Then, culture medium containing 10 ng ml -1 TNF-α was perfused into the engineered microvasculature for 12 h. To characterize the upregulated expression of adhesive molecules on the surface of TNF-α -stimulated HUVECs, the microvasculature was immunostained using a similar protocol to the one described NATure BiomeDiCAl eNgiNeeriNg above (without permearizing the cells). The primary antibodies included mouse monoclonal anti-human E-selectin (CD62E) (1:100; Thermo Fisher Scientific), mouse monoclonal anti-human ICAM-1 (15.2) (1:100; Thermo Fisher Scientific), mouse monoclonal anti-human VCAM-1 (BBIG-V1) (1:100; R&D Systems) and mouse monoclonal anti-human P-selectin (AK4) (1:100; Santa Cruz Biotechnology). Goat anti-mouse AF488 was used as the secondary antibody. To study how the endothelial barrier function recovered over time, permeability assays were performed immediately after, and 2 and 4 days after, 12 h TNF-α stimulation.
To study how free haemin affected endothelial barrier function, culture medium containing 5 or 10 μ M free haemin (Sigma-Aldrich) was perfused into the engineered microvasculature for 1 h. The HUVEC permeability assessment was carried out one day before, immediately after, and one and three days after haemin exposure.
Investigation of the effects of sickle erythrocyte-endothelial cell interactions on endothelial barrier function in the engineered microvasculature. Sicklecell blood samples were collected from sickle-cell patients receiving hydroxyurea treatment. RBCs were isolated via centrifugation and washed with 1× PBS three times to remove most of the plasma proteins. Then, brightfield images of RBC smears were taken. The circularity of individual RBCs in the smear images was analysed using ImageJ, and the RBCs with circularity lower than 0.5 were determined as iSCs. In some experiments, isolated RBCs were first stained with Octadecyl Rhodamine B Chloride (R18; Thermo Fisher Scientific), then washed three times with 1× PBS. Isolated RBCs were resuspended in cell culture medium to reach a haematocrit of ~40%. In experiments using glutaraldehyde-stiffened RBCs, RBCs from healthy donors were isolated by centrifugation and washed with 1× PBS three times. RBCs were then exposed to 0.065% (w/v) glutaraldehyde for 30 min, followed by washing with 1× PBS 6 times to remove the glutaraldehyde residue. These glutaraldehyde-stiffened RBCs were then mixed with normal RBCs at a ratio of 3:5 and resuspended in cell culture medium to reach a haematocrit of ~40%. The cell culture medium for resuspending RBCs contained 1 unit ml -1 hirudin (Sigma-Aldrich), which deactivated the residue thrombin in the medium and avoided the formation of tiny fibrin aggregates. The resuspended RBCs were perfused into the engineered microvasculature for 4 h, at the end of which the perfusion of sickle RBCs was recorded by videomicroscopy ( Supplementary  Videos 4 and 5) . The permeability assay was also carried out immediately after, and one and two days after, the 4 h perfusion of sickled RBCs. In the experiments using R18-stained RBCs, the engineered microvasculature was stained first with Hoescht 33342 before perfusion of the R18-stained RBCs. After perfusion of the R18-stained RBCs for 4 h, BSA-AF488 was perfused into the engineered microvasculature, and the microchannel occlusion and BSA-AF488 leakage from the occluded microchannels were imaged using a confocal microscope.
Culture of human malaria parasites. P. falciparum clones 3D7 and W2 were cultured under standard conditions using human O+ blood in RPMI-1640 medium supplemented with 10% pooled human AB serum. Cultures were maintained in a 37 °C incubator under an atmosphere of 5% CO 2 . Parasite density was determined by Giemsa staining of thin blood smears, and a density of at least 3% iRBCs at mixed stages was used for our experiments.
Investigation of the effects of endothelial interactions with iRBCs and TNF-α on endothelial barrier function in the engineered microvasculature. iRBCs were isolated via centrifugation and resuspended in cell culture medium to reach a haematocrit of 40%. The resuspended iRBCs were perfused into the non-TNF-α -stimulated or TNF-α -stimulated engineered microvasculature for 4 h, at the end of which, perfusion of the iRBCs was recorded using videomicroscopy (Supplementary Video 6). The permeability assay was carried out immediately after, and one and two days after, perfusion of the iRBCs.
Statistical analysis. GraphPad Prism version 5.0 (GraphPad Software, https:// www.graphpad.com/scientific-software/prism/) was used for all calculations. Statistical analyses were performed using Student's t-tests or one-or two-way analysis of variance (ANOVA), with Bonferroni's post-test determined by sample distribution and variance. Differences at P < 0.05 were considered statistically significant. Figures were prepared using GraphPad Prism (GraphPad Software). All data points are derived from three or more biological or technical replicates, as indicated for each experiment.
Study approval. Informed consent was obtained for all subjects. All protocols were approved by the Emory University Institutional Review Boards.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability.
The data that support the findings of this study are available within the paper and its Supplementary Information. Source data for the figures in this study are available in figshare at https://figshare.com/s/0921c553a279f77b41a7. 
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All the devices used for the experiments were pre-checked to make sure that the permeability is good for further experiments. All attempts at replicates were successful.
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Describe how samples/organisms/participants were allocated into experimental groups.
Devices were randomly allocated to each experimental groups. The samples from the sickle-cell patients were grouped on the basis of the ratio of irreversibly sickled red blood cells.
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Investigators were blinded to all clinical information of the patients who donated blood, aside from the primary diagnosis.
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A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
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See the web collection on statistics for biologists for further resources and guidance. Describe the software used to analyze the data in this study.
We used the statistical analysis module in the software Graphpad prism version 5.
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Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
All materials employed in this study are commercially available.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). c. Report whether the cell lines were tested for mycoplasma contamination.
The cells lines were not tested for mycoplasma contamination.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
No animals were used.
